Showing 2682 results for "amyotrophic lateral sclerosis (ALS)"

Neuronata-R improved function, survival in slow-progressing ALS

Neuronata-R (lenzumestrocel), an investigational stem cell therapy from Corestemchemon significantly improved function and reduced markers of nerve cell damage in a subgroup of people with slow-progressing amyotrophic lateral sclerosis (ALS), the final results of a Phase 3 clinical trial show. The ALSummit trial (NCT04745299) failed to meet…

Young investigators receive MGH awards for ALS research

Three researchers at Massachusetts General Hospital (MGH) have received 2025 MGH ALS Young Investigator Awards for their research on genetic abnormalities, faulty energy systems, and why some nerve cells are more susceptible to damage than others in amyotrophic lateral sclerosis (ALS). The awards announced by the Sean M.

Neurosense, awaiting Canada approval, scales PrimeC production

Neurosense Therapeutics said it’s scaled production of PrimeC, its oral therapy for amyotrophic lateral sclerosis (ALS), to commercial levels as it awaits regulatory approval to launch the medication in Canada. “This manufacturing milestone represents a critical leap forward in our commercialization roadmap,” Alon Ben-Noon, CEO of Neurosense, said in…

Eli Lilly licensing AIchemab’s ALS antibody therapy in $415M deal

Alchemab Therapeutics has entered into a licensing agreement with Eli Lilly to develop and market ATLX-1282, a therapy candidate for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions. ATLX-1282 was developed using Alchemab’s platform, which uses machine learning and artificial intelligence (AI) to identify potential therapeutic targets for diseases…

FDA clears expanded access program for SPG302 in ALS patients

Note: This story was updated May 13, 2025, to correct information about the company’s clinical trials. Spinogenix has received clearance from the U.S. Food and Drug Administration (FDA) to launch an expanded access program (EAP) for SPG302, its oral treatment for amyotrophic lateral sclerosis (ALS). EAPs, also known…

A mayday call to raise awareness of ALS, this month and beyond

Fire the flare guns, turn on the ship-to-shore radio, and holler “Mayday! Mayday! Mayday!” That’s the first order of business for a ship that’s sinking. It needs attention — lots of attention. There’s even an official mayday relay procedure, which lets ships in the vicinity take turns relaying the distress…